Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wild-type inactivated poliovirus vaccine + sabin inactivated poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This vaccination regimen involves the sequential administration of wild-type inactivated poliovirus vaccine (wIPV) and Sabin-strain inactivated poliovirus vaccine (sIPV). Developed and evaluated by Sinovac Biotech, this approach is designed for the prevention of poliomyelitis in infants. wIPV is derived from wild-type poliovirus strains (Mahoney, MEF-1, and Saukett), while sIPV is derived from attenuated Sabin strains. The sequential use of these vaccines aims to optimize immunogenicity and safety, potentially leveraging the different antigenic properties of the two vaccine types to ensure robust protection against all three types of poliovirus (Type 1, 2, and 3) while adhering to global polio eradication strategies that favor the use of Sabin-strain vaccines for safer manufacturing.
- Other names
- Sequential sIPV and wIPV VaccinationSequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
Beyond the preview
Go deeper on wild-type inactivated poliovirus vaccine + sabin inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wild-type inactivated poliovirus vaccine + sabin inactivated poliovirus vaccine.